TrialHuman vaccines & immunotherapeutics2014

A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.

Keith S Reisinger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.